Skip to content
ES
MARKETS / NASDAQ / SCYX
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Scynexis Inc. SCYX

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$20.6M
▲ 449.9% YoY
$-8.6M
In brief

What this company does

We do not own or operate and do not intend to own or operate facilities for manufacturing, storage and distribution, or testing of drug substance or drug product. As of March 1, 2026, we are the owner of more than 10 issued U.S. patents and more than 135 issued non-U.S. patents with claims to novel compounds, compositions containing them, processes for their preparation, and their uses as pharmaceutical agents, with terms expiring between 2027 and 2038. As of March 1, 2026, we had 18 employees, all of whom were employed on a full-time basis. We were incorporated in the State of Delaware on November 4, 1999. Our corporate headquarters are located at 1 Evertrust Plaza, 13th Floor, Jersey City, New Jersey 07302.

Written from the business description in SCYNEXIS, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 4 March 2026. Every sentence was checked against that document before publication.

Growth
USD 20.6M
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2025 · Revenue 20.6 · Net income -8.6
50.0M100.0M-25.0M-50.0M2013201520172019202120232025
Compound annual growth
+59.4%
+55.0%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−42 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -78.0% · Net -41.8%
-20000%-40000%2013201520172019202120232025
ROE
FY2025 · ROE -16.5%
50%100%150%-100%-200%-300%2013201520172019202120232025
Gross margin—
Operating margin-78.0%
Net margin-41.8%
Return on assets-11.5%
EBITDA—

Each USD of equity lost 16 cents this year.

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2021 · FCF -54.6
-20M-40M2013201520172019202120232025
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Total assetsUSD 59.0M
EquityUSD 49.4M
CashUSD 21.3M
Current ratio7.04×

Equity funds 84% of total assets.

The 13-year record
13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B0.00.00.10.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.00.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B····−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.0−0.0−0.0−0.00.0−0.00.00.00.0−0.00.0
Net income $B−0.0−0.00.1−0.1−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B····−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.17−0.441.39−1.47−1.25····−1.58−2.68−2.69−139.47
Dividend / sh $·············
Payout %·············
ROE %−16.5−33.3176.0−282.3−102.7−309.6−243.5−47.4−89.1−78.1−86.6··
Shares out B0.040.040.040.030.030.020.010.050.030.020.010.010.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 50 reconciliationsAUDITED

Reconciled in 13 of 19 fiscal years. 45 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013

Share this section

Download image